(lp0
S'Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B.'
p1
aS'Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire  - Feb 28, 2017 &quot;Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy,&quot;&nbsp;...SANGAMO THERAPEUTICS, INC.  Files An 8-K Results of Operations ... - Market Exclusive'
p2
aS'Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference ... PR Newswire  - Feb 21, 2017 RICHMOND, Calif., Feb. 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market&nbsp;...'
p3
aS'Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For ... PR Newswire  - Feb 27, 2017 RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, today announced that the U.S.Sangamo  Announces Rare Pediatric Disease Designation From FDA For SB-318 - StreetInsider.com'
p4
aS'Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the U.S.'
p5
aS'Sangamo Therapeutics Inc. MarketWatch - Dec 21, 2009 Check out the returns on our 8 Lazy Portfolios that are made up of low-cost buy-and-hold index funds.  How to create your own Lazy Portfolio.'
p6
aS'SANGAMO THERAPEUTICS, INC.  Files An 8-K Departure of Directors ... Market Exclusive - Feb 25, 2017 On February 21, 2017, Dr. Dale Ando and Sangamo Therapeutics, Inc.  entered into a separation agreement .'
p7
aS"BRIEF-Sangamo Therapeutics announces CFO succession Reuters - Feb 27, 2017 SANTIAGO, March 11 The striking union at BHP Billiton's Escondida copper mine in Chile, the world's largest, told Reuters on Saturday that it will not accept an offer from the company to return to the negotiating table, and it called on the company to ..."
p8
aS"Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug ... PR Newswire  - Jan 5, 2017 5, 2017 /PRNewswire/ -- Sangamo BioSciences, Inc.  today announced that the U.S. Food and Drug Administration  has cleared the Company's Investigational New Drug application  for its SB-525 gene therapy program for the treatment ...FDA OKs Sangamo's IND for gene therapy candidate for hemophilia A; shares ... - Seeking AlphaSangamo Biosciences  Reports FDA Clearance of IND for SB-525 Gene ... - StreetInsider.com"
p9
aS"Brokerages Set Sangamo Therapeutics Inc  PT at $5.67 Chaffey Breeze - Mar 10, 2017 Sangamo Therapeutics logo Sangamo Therapeutics Inc  has been given a consensus rating of Hold by the seven brokerages that are presently covering the firm.Stock Returns: Osiris Therapeutics Inc  versus Sangamo ... - CML NewsSangamo Therapeutics, Inc.'s  stock price is Worth at $4.35 while ... - Hot Stocks Point"
p10
a.